Press Release | December 21, 2023

Minapharm Pharmaceuticals and Cheerland Biotechnology Sign a Memorandum of Understanding towards a Strategic Partnership in the MEA Region and Asia

Cairo, Egypt – Shenzhen, China -- Dec 21.12.2023

Minapharm Pharmaceuticals, a premier biopharmaceutical company in the Middle East and Africa and global provider of proprietary technologies, headquartered in Egypt with multiple global subsidiaries, and Cheerland Biotechnology (CLB), a global biologics contract development and manufacturing organization based in China, today, December 21st, 2023, announced the signing of a Memorandum of Understanding (MoU) with the aim of jointly pursuing potential business opportunities in the MEA region and Asia.

The partnership aims to leverage the regional biotech leadership of Minapharm in the MEA region with that of Cheerland in China and Asia, to synergize their expertise in the development, large-scale manufacturing, and commercialization of high-quality biologics for global market access.

The partnership will integrate Cheerland’s large-scale bioreactor expertise and state-of-the-art technology with Minapharm’s longstanding strengths in the development and end-to-end manufacturing of biologics and impressive therapeutic pipeline using Minapharm’s latest manufacturing facility in Cairo with the aim of advancing healthcare solutions and meeting the growing global demand for high-quality biologics.

This MoU marks an important step towards expediting the development and manufacturing of high quality and affordable biological therapies for patients in the middle east and Africa as well as in China and the rest of Asia.

Dr. Shaheer Bardissi, Co-CEO and Executive Board Member of Minapharm pharmaceuticals, said “This move envisages a geographic expansion strategy for Cheerland to access the Middle East and Africa whilst granting Minapharm a gateway to the surging biopharma market and innovation in China. The collaboration is an important step to enable a cutting-edge bioprocess and biomanufacturing platform across three continents.”

Mr. Daniel P. Brindle, Chief Executive Officer of Cheerland Biotechnology, said “We are excited to develop a long-term partnership with Minapharm, as together we will build a strong foundation for patients across these important regions.” Mr Ruyin Liu, Chairman of Cheerland Biotechnology, said following the signing of the MOU,” At Cheerland, our mission is to make the world a healthier place with our products and services. The Middle East and Africa region is our first entry into the international market, and the partnership with Minapharm is an important milestone for Cheerland in our quest to become a global leader in biologics CDMO.”

About Minapharm Pharmaceuticals

Minapharm Pharmaceuticals is a leading pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical company in Africa with over 20 years of experience in cellular and bioprocess engineering. Headquartered in Cairo, Minapharm commercializes over 100 life-saving and life-enhancing products ranging from small molecules to complex genetically engineered proteins, with an impressive immunotherapy pipeline. Together with its wholly-owned Berlin-based subsidiary, ProBioGen AG, a globally renowned CDMO and provider of innovative proprietary technologies in the fields of monoclonal antibodies, protein, viral, and cell therapies to the global biotech industry at large, Minapharm has established an integrated business model making it to date the only gene-to-market biopharmaceutical company in the region. Minapharm employs a collective workforce of over 2,000 and is listed on the Cairo and Alexandria stock exchanges (Symbol: MIPH).

About Cheerland Biotechnology

Founded in 2021 in Shenzhen, China, Cheerland Biotechnology (CLB) is a leading biologics contract development and manufacturing organization (CDMO). Led by an international team with extensive experiences in the biotech industry, CLB provides global biotech and biopharma clients with world-class facilities featuring the first 15kL bioreactors in China, robust process design, digital quality systems, and compliance with cGMP standards and global regulatory requirements. Currently CLB is building state-of-the-art CDMO plants in Shenzhen, Shanghai and Abu Dhabi, with a total capacity of ~1 million liters by 2025. Cheerland Biotechnology, the World’s Local CDMO.